BridgeMD
Rezafungin plasma concentrations in patients with or without extracorporal treatments (ECMO ± RRT) (REZAFECT)
EU CTIS ID: 2024-519789-37-00
What this study is testing
To evaluate Rezafungin plasma concentrations in patients with ECMO (with or without RRT) receiving Rezafungin for treatment of invasive fungal infection in critically ill patients with extracorporeal treatments.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- ICU patient with ≥18 years of age
- ECMO support (iLA active or others) or Critically ill patients receiving Rezafungin for treatment of invasive fungal infection without extracorporeal treatments will be recruited by study team members and data will be used for comparative analysis ± RRT
- Rezafungin administration
- Prior written informed consent (IC) in counscious patients; in inconscious patients the IC will be obtained after arousal.
You likely can't join if
- Known hypersensitivity to Rezafungin or other echinocandins
- Pregnant or breastfeeding
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.